Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2012

View Archived Issues

Taisho Pharmaceutical announces new GlyT1 inhibitors

New Exp1 inhibitors show promise in a number of in vitro and in vivo cancer studies

Morphotek evaluates MORAb-004 in new phase II trial

BioAlliance plans phase II Clonidine Lauriad study expansion

FDA requests more information for HyQ BLA

PRINT nanofabrication allows precision synthesis of therapeutic particles

Merck & Co. selects lead from new series of phosphodiesterase 10A inhibitors

Sanofi presents novel oncolytic drug candidate

Preclinical results demonstrate significant early antitumor efficacy of new immunotherapy

Johnson & Johnson reviews progress of first quarter 2012

DFH Pharma and NIH collaborate on development of HIV drugs

Abbott in-licenses Stanford University biomarkers for prostate cancer

Dyax and Eclipse Therapeutics enter licensing agreement

Highly potent and selective EZH2 inhibitors discovered by GSK

Depomed plans NDA filing for Serada

Novel ERK inhibitors designed

Novel PI3Kalpha/mTOR inhibitors developed at Hutchison MediPharma

Exelixis scientists discover new JAK1 inhibitors

New lysophospholipid S1P1 receptor agonists patented

Treatment begins in phase II IMO-3100 trial

Melanoma trial of SCIB-1 clear to advance to phase II

Intellect Neurosciences collaborates with leading Alzheimer's research group

AMRI enters into development and manufacturing deal

ImmunoGen reports advances in its anticancer drug pipeline

GE Healthcare enters Alzheimer's disease collaboration

Confirmatory data support efficacy of Phytopharm ALS candidate drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...